Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,237 total articles
I added to my MACOM (MTSI) position on the pullback below $310. The business is increasingly exposed to AI-driven data-center optical demand, recently reported double-digit revenue growth, and has taken steps to shore up supply chain risk. Technically, price sits near its 50-day EMA providing a concise entry with defined downside. This is a mid-ter…
Veracyte (VCYT) runs a diversified diagnostics portfolio (Afirma, Percepta, Envisia) that is producing positive free cash flow and a tidy balance sheet. Valuation looks reasonable against cash generation; technicals are soft, presenting a tactical entry opportunity. This trade idea lays out an entry at $47.50 with a $60.00 target and a $42.00 stop …
Gilead Sciences looks cheap to cash-flow, not to headline multiples. With $12.9B in free cash flow, a durable HIV/viral franchise, and multiple near-term clinical and commercial catalysts, the market appears to be underpricing growth potential. I upgrade GILD to a constructive long and lay out an actionable trade plan with entry, stop and targets a…
Greg Abel has started to deploy Berkshire's record cash balance aggressively: Q2 saw the largest buyback in five years, a $6.8B acquisition of Taylor Morrison and a meaningful bump into Alphabet. At roughly $780k per Class A share, Berkshire trades at a reasonable P/E and still generates meaningful free cash flow. This trade targets a mid-term pop …
Verizon combines a strong cash flow profile, an above-market dividend yield, and fresh revenue upside from large dark-fiber and AI infrastructure deals. Valuation is reasonable by telecom standards and technicals support additional upside. This trade idea outlines an actionable long position with entry, stop and target, a clear time horizon, and a …
Aspen Aerogels designs advanced aerogel insulation used in energy infrastructure and is pushing into EV thermal management. The shares trade like a sub-$1B materials small cap with improving technicals and clear end-market tailwinds from EVs and decarbonization. This trade aims to capture re-rating as commercialization milestones and volume ramp ev…
Palantir just reported blowout growth and now sits on a multi-billion dollar contract backlog. The market is finally responding; momentum is strong, but the stock is richly priced. This trade idea offers a defined long with a 180-trading-day horizon, explicit entry, stop and target, and a balanced look at catalysts and risks.
Flywire (FLYW) has seen its margins compress as the business reinvests in growth and integration projects. The market is treating that as a structural problem; we see a temporary hit to margins against durable revenue growth, solid free cash flow ($159.2M trailing), and a reasonable valuation (P/S ~3.0). This trade targets a rebound as operating le…
Blue Owl has been punished with headline risk and heavy short interest, but its underlying economics - $1.32B in free cash flow, a $19B market cap, and a dividend supported by recurring fee income - argue for a constructive trade. This is a tactical long: enter near current levels, protect with a defined stop, and target meaningful upside as flows …
Assured Guaranty (AGO) has tumbled into oversold territory after a heavy session that left the shares near the 52-week low. Fundamentals remain intact: ~$3.3B market cap, P/E below 10, price-to-book around 0.6 and a modest quarterly dividend. This trade targets a mean-reversion recovery toward $85 while keeping a tight stop under recent support.
Sandisk plunged after guiding conservatively and prioritizing long-term contracts worth roughly $93.9 billion. The market punished near-term growth misses; we see a tradeable long where consensus is overly focused on the cycle and is underweight the value of multi-year contracted revenue and strong cash generation. Entry at current levels, tight st…
Agnico Eagle combines scale, a steady dividend and a diversified asset base across high-quality deposits. At a market cap of ~$103.8B and a trailing PE of ~12.6, the stock looks fairly valued for a top-tier producer and still has room to run toward $220 with continued gold strength and steady operational execution. Technical momentum is bullish, bu…
Meta's free cash flow has softened relative to its size, leaving the stock stretched on a P/FCF basis. Still, the company is doubling down on AI and infrastructure with capex guidance that should boost ad targeting and monetization over the next 12-18 months. This trade idea buys that optionality at $604.01, uses a $540 stop, and targets $720 over …
Berkshire reported solid operating earnings growth, increased repurchases and continues to generate meaningful free cash flow. At roughly $1.12T market cap and a P/E near 15.5, the stock offers a conservative equity exposure with management buying back shares aggressively. I lay out a mid-term trade with explicit entry, stop and target, plus the ke…
Shopify posted 34% revenue growth and a tripling of AI-driven orders in Q2, reaffirming its role as the infrastructure layer for modern commerce. The platform's GMV scale, recurring merchant revenue, and expanding services mix justify paying up, but the stock trades at premium multiples. This trade targets a breakout above the 52-week high with a d…
Schneider’s diversified transport mix, recent accretive M&A and a low leverage profile make it a compelling swing trade as industry pricing and volumes recover. Entry at $36.00, stop $33.00, target $41.50 over a 45 trading day horizon.
Nvidia has turned the messy economics and engineering overhead of AI into a product-led moat. Exceptional margins, huge free cash flow and tight competitive differentiation justify paying up, but the valuation leaves little margin for cyclical weakness. This trade targets a measured long exposure with a mid-sized position, defined stop and a 34% up…
Meta is investing aggressively in AI infrastructure, which suppresses near-term free cash flow. With $40.98B in trailing free cash flow, a $1.51T market cap and attractive operating returns, the company is positioned to produce a sharp FCF recovery once capex cools and AI monetization scales. This trade idea outlines a pragmatic long (buy) with ent…
Betterware de México (BWMX) combines a low-teens P/E, a recently closed $250M Tupperware Latin America acquisition at a bargain multiple, and a meaningful dividend yield. With clear synergies in manufacturing and distribution across Mexico and Brazil, the stock looks attractively priced around $16.70. This trade plan targets $22.50 over a long-term…
Colony Bankcorp (CBAN) finished a strong fiscal run, trades near its 52-week high but remains inexpensive on several measures. We lay out a tactical long with strict risk controls and a 46-180 trading day time frame to capture a valuation re-rating and continued FCF conversion.
Northern Star Resources has completed a multi-year capex cycle. With large processing investments now commissioned and sustaining spend set to fall, the company is positioned to convert production into outsized free cash flow. We view this as a constructive structural change that supports a buy: entry $11.50, target $15.00, stop $9.50 over a 180 tr…
L3Harris sits squarely in the crosshairs of a defense spending rerating: strong backlog across missiles, sensors and battlefield communications, a high-margin propulsion business (Aerojet Rocketdyne), and healthy free cash flow. At $288 the stock offers asymmetric upside into persistent geopolitical-driven procurement tailwinds while trading at rea…
Corvus (CRVS) is a strong buy into clinical catalysts tied to its atopic dermatitis candidate soquelitinib and ongoing T-cell lymphoma programs. The company has fresh capital from an upsized offering, meaningful insider buying, and clear trial traction that has already driven strong YTD performance. This trade idea outlines an actionable entry, sto…
Tyra Biosciences (TYRA) is a clinical-stage precision oncology company valued at roughly $1.58B. With a pipeline focused on selective FGFR inhibition and a binary clinical catalyst in SURF302, TYRA offers a high-risk, high-reward trade: a positive readout could re-rate the stock materially, while negative data would likely compress the valuation. T…
Amazon's latest quarter delivered a stronger-than-expected operational beat that re-established the case for owning the stock. The core drivers are continued strength in cloud demand, improving advertising monetization, and structural margin recovery in retail logistics. This trade idea lays out an actionable long with precise entry, target, and st…
